Hemophilia Treatment Market

Hemophilia Treatment Market size reached USD 12.1 billion in 2021 and is estimated to reach USD 18.3 billion in 2029 and the market is estimated to grow at a CAGR of 5.3%.

To have an edge over the competition by knowing the market dynamics and current trends of “Hemophilia Treatment Market”, request for Sample Report here

Market Dynamic

Key Drivers and Emerging Trends

One of the major factors propelling the Hemophilia Treatment market includes increasing incidences of hemophilia across the world. As per the World Federation of Hemophilia, in October 2021, nearly 209,614 people were diagnosed with hemophilia. In addition, strategic government initiatives which include grants for the research on hemophilia is projected to strengthen the Hemophilia Treatment Market Share. For example, the National Heart, Lung, and Blood Institute provided an allowance for USD 12 million to Indiana University School of Medicine researcher for the development on hemophilia medicine.

With the emerging need to improve life quality of patients, adoption of treatments like replacement and gene therapy has increased, driving the Hemophilia Treatment Market Size. However, high treatment cost and insufficient knowledge among individual about the use of advanced technologies is expected to impede the market growth over the upcoming years.

Do you want to know more about the Research process and detailed Methodology, Request Research Methodology of this report

Product – Segment Analysis

Based on the Product, the Recombinant coagulation factor concentrates segment is expected to grow at a higher CAGR during the forecast period. This can be attributed to the new recombinant pipeline gene therapies and agents, like valoctocogene roxaparvovec (phase 3 candidate) and Fitusiran (phase 3 trials). Recombinant clotting factors are produced in a lab. They don’t come from blood. They are prepared with recombinant DNA technology. They are concentrated into a powder form which is then mixed with sterile water and injected.

Type – Segment Analysis

Based on the Type, the Hemophilia A segment is expected to grow at a higher CAGR during the forecast period. This is the most common type, is caused by a deficiency of factor VIII, one of the proteins that aids blood to form clots. This type is known as classic hemophilia. In 2020, according to the US Centers for Disease Control and Prevention (CDC), it was diagnosed in approximately 1 in 5,617 live male births. There are between 30,000 – 33,000 males diagnosed with this disorder in the US.  More than half of people diagnosed with hemophilia A have a severe condition. Type A is four times as common as Type B. It affects all races and ethnic groups.

In case, any of your pain points areas are not covered in the current scope of this report, Request for Free Customization here

Regional – Segment Analysis:

Based on the region, the North-America region is projected to dominate the market during the forecast period. This can be attributed owing to the rising cases of bleeding disorder and their rising seriousness, growing use of recombinant products, rising adoption of prophylaxis treatment, the rising capability of effective gene therapy, and the regional proximity of key market players. North America is estimated to sustain its top position over the forecast time period. Additionally, increasing R&D investments of hemophilia products and advancing medical knowledge are also contributing to the growth of the hemophilia market share in this region. The U.S. is a major market player in the North American market due to huge government support, rising patient pool suffering from hemophilia and rising use of available medicine.

Top Market Players

Various notable players operating in the market include Baxter, Grifols, S.A., CSL Limited, Octapharma AG, Novo Nordisk A/S, Kedrion S.p.A, Pfizer Inc., Bayer AG, Biogen, Hospira, Inc, among others.

Key Developments:

• • In 2022, BioMarin Pharmaceutical Inc. completed a two-year analysis of the Phase 3 GENEr8-1 study and valoctocogene roxaparvovec, an investigational gene therapy to treat adults with severe hemophilia A, at the 15th Annual Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD).
  • 2022, Novo Nordisk declared the expansion of product offerings to support Canadians suffering with hemophilia A. The expansion made ESPEROCT® (Antihemophilic Factor VIII (Recombinant, B-Doman Truncated), PEGylated) and ZONOVATE® (Antihemophilic Factor (Recombinant, B-Domain Truncated) publicly available through Canadian Blood Services starting April.1, 2022.
  • In 2021, Grifols donated 240 million international units (IU) of blood clotting factors for eight years to consistently treat around 3,000 bleeding disorder patients in developing countries.
  • In 2021, CSL Limited closed a license agreement for a haemophilia B gene therapy candidate which was positive, but there are still risks aligned with competition and regulatory approvals.

Segments covered in the Report:

The global Hemophilia Treatment market has been segmented on the basis of Product, Type, and regions. Based on Product, the market is segmented into Plasma derived coagulation factor concentrates, Recombinant coagulation factor concentrates, Desmopressin and Antifibrinolytic agents. Based on Plasma derived coagulation factor concentrates, the market is further segmented into Factor VIII, Factor IX, Factor XIII, Activated prothrombin complex concentrate and Von willebrand factor. Based on Recombinant coagulation factor concentrates, the market is further segmented into Factor VIII, Factor IX and Von willebrand factor.  Based on Type, the market is segmented into Hemophilia A, Hemophilia B and Hemophilia C. 

For detailed scope of the “Hemophilia Treatment Market” report request a Sample Copy of the report

Key questions answered in this research report:

• • At what pace is global Hemophilia Treatment market growing? What will be the growth trend in the future?
  • What are the key drivers and restraints in Hemophilia Treatment market? What will be the impact of drivers and restraints in the future?
  • What are the regional revenues and forecast breakdowns? Which are the major regional revenue pockets for growth in the global Hemophilia Treatment market?
  • Which Product generated maximum revenues in 2021 and identify the most promising Product during the forecast period?
  • What are the various Type areas of global Hemophilia Treatment market and how they are poised to grow?
  • What companies are the major participants in this market and their business strategies, how does the competitive landscape look like?

Market Segmentation

Global Hemophilia Treatment Market by Product

• • Plasma derived coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Factor XIII
    • Activated prothrombin complex concentrate
    • Von willebrand factor
  • Recombinant coagulation factor concentrates
    • Factor VIII
    • Factor IX
    • Von willebrand factor
  • Desmopressin
  • Antifibrinolytic agents

Global Hemophilia Treatment Market by Type

• • Hemophilia A
  • Hemophilia B
  • Hemophilia C

Global Hemophilia Treatment Market by Region

• • North America Hemophilia Treatment Market (Option 1: As a part of the free 25% customization)
    • By Product
    • By Type
    • US Market All-Up
    • Canada Market All-Up
  • Europe Hemophilia Treatment Market (Option 2: As a part of the free 25% customization)
    • By Product
    • By Type
    • UK Market All-Up
    • Germany Market All-Up
    • France Market All-Up
    • Spain Market All-Up
    • Rest of Europe Market All-Up
  • Asia-Pacific Hemophilia Treatment Market (Option 3: As a part of the free 25% customization)
    • By Product
    • By Type
    • China Market All-Up
    • India Market All-Up
    • Japan Market All-Up
    • Rest of APAC Market All-Up
  • RoW Hemophilia Treatment Market (Option 4: As a part of the free 25% customization)
    • By Product
    • By Type
    • Brazil Market All-Up
    • South Africa Market All-Up
    • Saudi Arabia Market All-Up
    • UAE Market All-Up
    • Rest of world (remaining countries of the LAMEA region) Market All-Up

Major Players Operating in the Hemophilia Treatment (Option 5: As a part of the Free 25% Customization – Profiles of 5 Additional Companies of your Choice)

• • Baxter
  • Grifols, S.A.
  • CSL Limited
  • Octapharma AG
  • Novo Nordisk A/S
  • Kedrion S.p.A
  • Pfizer Inc.
  • Bayer AG
  • Biogen
  • Hospira, Inc